ViaDerma Provides an Update to Shareholders via a Letter from the CEO
The Company is also in early stage discussions to sell its product on TV
LOS ANGELES, July 12, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has posted a from President and CEO, Dr. Christopher Otiko on the Company’s website, .
The letter contains updates on future sales, Dr. Otiko’s recent trip to India as well as several other key developments. Some of the other items in the letter include:
- Registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA is in the final stages and expected to be completed very soon. At that time, Vage Nigeria Ltd. will pay a 50% deposit to ViaDerma in the amount of $125,000 for its initial order worth $250,000.
- Discussions with a South American distributor are ongoing and expected to result in a purchase of 200,000 units of Vitastem per month.
- The Company is realizing significant month to month increases in Vitastem sales on Amazon.
- Registering of Vitastem for medical insurance coverage is underway and expected to have final approval for insurance payments and reimbursements for January 2019.
Additionally, the Company is announcing they are close to finalizing a sales agreement for 10,000 units per month of Vitastem with a distributor in Vietnam.
Also, ViaDerma is in early stage discussions to have their product, Viastem sold in Direct Response ads on TV, and distributed through a network of 600 Skilled Nursing Facilities in California and 5000 hospitals in the east coast.
ViaDerma President, Dr. Christopher Otiko said, “As I pointed out in my recent letter to shareholders, we are very excited about our future and our current trajectory. In spite of some minor delays, we remain optimistic this will be a very strong year for ViaDerma.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit:
Contact information:
Investor Relations
Email:
Phone: 310-374-6111
